An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections
Latest Information Update: 08 Aug 2025
At a glance
- Drugs Meropenem/vaborbactam (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms TANGOKIDS
- Sponsors Melinta Therapeutics; Rempex Pharmaceuticals
Most Recent Events
- 25 Jul 2025 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2025 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.
- 10 Jul 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.